1Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J,2007,28 : 1462 - 1536.
2Weber MA, Julius S, Kjeldsen SE,et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial[ J]. Lancet,2004,363:2049- 2051.
3Pepine C J, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease [J]. J Am Coll Cardiol,2006,47:547 -551.
4Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[ J ]. Lancet, 2004,363:2022 - 2031.
5Dahlof B, Sever PS, Pouher NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomised controlled trial [J].Lancet,2005,366 : 895 - 906.
6Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group [ J ]. Jama, 2000,283 : 1967 - 1975.
7Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved trial [ J ]. Lancet, 2003, 362:777 -781.
